WETENSCHAPPELIJKE OUTPUT THORAXCENTRUM UMCG, 2008
|
|
|
- Lionel Cummings
- 10 years ago
- Views:
Transcription
1 WETENSCHAPPELIJKE OUTPUT THORAXCENTRUM UMCG, 2008 Dissertaties 1. Geluk CA Coronary risk stratification. From PREVEND to the prevention of coronary events. ISBN: Promotiedatum: 16 januari 2008 Prof.dr. W.H. van Gilst Prof.dr. J.L. Hillege 2. Dieperink W Multiple applications of the Boussignac continuous positive airway pressure system. ISBN: Promotiedatum: 20 februari 2008 Prof.dr. L.P.H.J. Aarts Copromotores: Dr. M.W.N. Nijsten Mw.Dr. T. Jaarsma 3. Smit JJJ Platelets and White Blood Cells in Acute Coronary Syndromes ISBN: Promotiedatum: 23 april 2008 Promotor: Copromotores: Dr. A.W. van t Hof Dr. J.P. Ottervanger 4. Vogelzang M Computer assisted decision support in acutely ill patients. Application in glucose management and quantification of myocardial reperfusion ISBN: Promotiedatum: 21 mei 2008 Promotor: Copromotor: Dr. M.W.N. Nijsten 5. Nienhuis MB Prognostic implications of myocardial injury around percutaneous coronary interventions ISBN: ISBN: (electronic version) Promotiedatum: 28 mei 2008 Prof.dr. H.J.G. Bilo Copromotor: Dr. J.P.Ottervanger 6. Groenewegen HC Therapeutic and mechanistic explorations of in-stent restenosis in the rat aortic stenting model ISBN: ISBN: (digital)
2 Promotiedatum: 18 juni 2008 Prof.dr. W.H. van Gilst Copromotores: Dr. B.J.G.L. de Smet Dr. A.J.M. Roks 7. Westenbrink BD Erythropoietin in Heart Failure. Pathology and Protection ISBN ISBN (elektronische versie_ Promotiedatum: 17 september 2008 Prof.dr. D.J. van Veldhuisen Copromotores: Prof.dr. W.H. van Gilst Dr. A.A. Voors Dr. R.G. Schoemaker 8. Hartog JWL Advanced glycation end-products in cardiac and renail failure ISBN ISBN-13 Digital version Promotiedatum: 3 december 2008 Promotor: Copromotores: Prof.dr. D.J. van Veldhuisen Dr. A.J. Smit Dr. A.A. Voors Dr. S.J.L. Bakker 9. Tan ES Advanced clinical approaches in complex cardiovascular disease. Invasive options at the crossroad of ischemia, heart failure and arrthythmias ISBN ISBN (digital version) Promotiedatum: 3 december 2008 Prof.dr. I.C. van Gelder Prof.dr. F. Zijlstrs Copromotor: Dr. G.A.J. Jessurun Publicaties Internationale tijdschriften The paramount importance of 12-lead electrocardiography in the management of patients with acute myocardial infarction Catheter Cardiovasc Interv 2008;71:613 Smit JJ, Ottervangfer JP, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gosselink AT, De Boer MJ,, Van t Hof AW; ON-TIME Study Group Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction Am J Cardiol 2008;101:446-51
3 Deuling JH, Vermeulen RP, Anthonio RA, Van den Heuvel AF, Jaarsma T, Jessurun G, De Smet BJ, Tan ES, Closure of the femoral artery after cardiac catheterization: a comparison of Angio-Seal, StarClose, and manual compression Catheter Cardiovasc Interv 2008;71: Belonje AM. Voors AA, Van Gilst WH, Anker SD, Slart R.H., Tio RA., Van Veldhuisen DJ; HEBE-III investigators Effects of erythropoietin aftera n acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III) Am Heart J 2008;155: Groenewegen HC, Onuta G, Goris M, Zandvoort A,, Van Gilst WH, Rozing J, De Smet BJ, Roks AJ, Hillebrands JL Non-bone marrow origin of neointimal smoot muscle cells in experimental in-stent restenosis J Vasc Res 2008;45: Vlaar PJ, Svilaas T, Van der Horst IC, Diercks GFH, Fokkema ML, De Smet BJGL, Van den Heuvel AFM, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJH, Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study The Lancet 2008;371: Vermeulen RP, Jessurun GA, Peels HO, Jaarsma T, Clinical performance indicators for percutaneous coronary intervention Crit Pathw Cardiol 2008;7: Ruifrok WPT, De Boer RA, Westenbrink BD, Van Veldhuisen DJ, Van Gilst WH Erythropoietin in cardiac disease: new features of an old drug Eur J Pharmacol 2008;585:270-7 Van Gelder IC on behalf of the EHRA Education Committee, Boriani G, Ernst S, Heidbuchel H, Zaza A, Mäkijärvi M, Gorenek B, Blomström Lundquist C Case of polymorphic ventricular tachycardia after stroke necessitating defibrillation Europace 2008;10:77-8 Wiesfeld AC Key questions are helpful to prevent an unnecessary pulmonary veins isolation ablation procedure Europace 2008;10:121; author reply 121 Van Gelder IC, Boriani G, Ernst S, Heidbuchel H, Zaza A, Mäkijärvi M, Gorenek B, Blomström Lundquist C on behalf of the EHRA Education Committee Case of the month by the EHRA Education committee: exercise-related arrhythmias Europace 2008;10:235-7 Buck S, Rienstra M, Maass AH, Nieuwland W, Van Veldhuisen DJ, Van Gelder IC Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time Europace 2008;10: Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC
4 New risk factors for atrial fibrillation: causes of not-so-lone atrial fibrillation Europace 2008;10: Smit AJ, Hartog JWL, Voors AA, Van Veldhuisen DJ Advanced glycation endproducts in chronic heart failure Ann NY Acad Sci 2008:1126: Van der Meer P, Van Veldhuisen DJ, Januzzi JL Erythropoietin in cardiovascular diseases: exploring new avenues Clinical Science 2008;114: Dobre D, De Jongste MJL, Haaijer-Ruskamp FM, Sanderman R, Van Veldhuisen DJ, Ranchor AV The enigma of quality of life in patients with heart failure Int J Cardiol 2008;125:407-9 Van der Harst P, Böhm M, Van Gilst WH, Van Veldhuisen DJ The case for statin therapy in chronic heart failure Clin Res Cardiol 2008;97: Lubbers DD, Willems TP, Van der Vleuten PA, Overbosch J, Götte MJW, Van Veldhuisen DJ, Oudkerk M Assessment of global left ventricular functional parameters: analysis of every second shortaxis magnetic resonance imaging slices is as accurate as analysis of consecutive slices Int J Cardiovasc Imaging 2008;24: Svilaas T, Vlaar PJJ, Van der Horst ICC, Diercks GFH, De Smet BJGL, Van den Heuvel AFM, Anthonio RL, Jessurun GAJ, Tan, ES, Suurmeijer AJH, Thrombus aspiration during primary percutaneous coronary intervention N Engl J Med 2008;358: Peels HO, Jessurun GAJ, Van der Horst ICC, Arnold AER, Piers LH, Outcome in transferred and nontransferred patients after primary percutaneous coronary intervention for ischaemic out-of-hospital cardiac arrest Catheter Cardiovasc Interv 2008;71: Hirsch A, Nijveldt R, Van der Vleuten P, Tio RA, Van der Giessen WJ, Marques KMJ, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WRM, Biemand BJ, Tijssen, JGP, Van Rossum AC, Piek JJ, Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: pilot study of the multicenter HEBE trial Catheter Cardiovasc Interv 2008:71: Stoel MG, Marques KMJ, De Cock CC, Bronzwaer JG, Von Birgelen C, High dose adenosine for suboptimal myocardial reperfusion after primary PCI: 1 randomized placebo-controlled pilot study Catheter Cardiovasc Interv 2008;71:283-9 Nienhuis MB, Ottervanger JP, Bilo HJG, Dikkeschei BD, Prognostic value of troponin after elective percutaneous coronary intervention. A metaanalysis. Catheter Cardiovasc Interv 2008;71:318-24
5 Van der Vleuten PA, Rasoul S, Huurnink W, Van der Horst ICC, Slart RH, Reiffers S, Dierckx RA, Tio RA, Ottervanger JP, De Boer MJ, The importance of left ventricular function in long-term prognosis after primary percutaneous coronary intervention BMC Cardiovasc Disord 2008;8:4 Van der Harst P, Groenewegen HC, Roks AJ, Buikema H,, Van Gilst WH, De Smet BLGL Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat Coron Artery Dis 2008;19:47-53 Peels JOJ, Anthonio RL, Jessurun GAJ, Mechanical intervention after thrombolysis J Cardiovasc Med 2008;9:15-21 Should we revascularize patients with moderate coronary lesions and borderline fractional flow reserve measurements? Editorial comment Catheter Cardiovasc Interv 2008;71: How to remove thrombus prior to stenting in patients with acute myocardial infarction? Catheter Cardiovasc Interv 2008;72:204 A novel delta-protein-kinase inhibitor for adjunctive therapy during percutaneous coronary intervention Nat Clin Pract Cardiovasc Med 2008;5:446-7 Dikkers R, Willems TP, Piers LH, De Jonge GJ, Tio RA, Van der Zaag-Loonen HJ, Van Ooijen PM,, Oudkerk M Coronary revascularization treatment base don dual-source computed tomography Eur Radiol 2008;18: Vlaar PJ, Diercks GF, Svilaas T, Vogelzang M, De Smet BJ, Van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, The feasibility and safety of routine thrombus aspiration in patients with non-stelevation myocardial infarction Catheter Cardiovasc Interv 2008;72: Aalbers JJJ, Waterbolk TW, Van Tintelen JP, Hillege, Boonstra PW, Van den Berg MP Prophylactic aortic root surgery in patients with Marfan syndrome: 10 years experience with a protocol based on body surface area Eur J Cardio-thorac Surgery 2008;34: Buck S, Maass AH, Nieuwland W, Anthonio RL, Van Veldhuisen DJ, Van Gelder IC Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy Eurospace 2008;10: Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ,
6 Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure J Cardiac Failure 2008;14: Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW,, Birgersdotter-green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK, for the PREPARE Study Investigators Strategic programming of detection and therapy parameters in implantable cardioverterdefibrillators reduces shocks in primary prevention patients J Am Coll Cardiol 2008;52: Gu YL, Fokkema ML, The emerging role of thrombus aspiration in the management of acute myocardial infarction Circulation 2008;118: Fokkema ML, Vlaas PJ, Svilaas T Thrombus aspiration as definitive mechanical intervention for ST-elevation myocardial infarction: a report of five cases J Invasive Cardiol 2008:20:242-4 Geluk CA, Dikkers R, Perik PJ, Tio RA, Götte MJ, Hillege HL, Vliegenthart R, Houwers JB, Willems TP, Oudkerk M, Measurement of coronary calcium scores by electron beam computer tomography or exercise testing as initial diagnostic tool in low-risk patients with suspected coronary artery disease Eur Radiol 2008;18: Smit JJ, Ottervangfer JP, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gosselink AT, De Boer MJ,, Van t Hof AW; ON-TIME Study Group Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction Am J Cardiol 2008;101: Deuling JH, Vermeulen RP, Anthonio RA, Van den Heuvel AF, Jaarsma T, Jessurun GA, De Smet BJ, Tan ES, Closure of the femoral artery after cardiac catheterization: a comparison of Angio-Seal, StarClose, and manual compression Catheter Cardiovasc Interv 2008;71: Belonje AM. Voors AA, Van Gilst WH, Anker SD, Slart R.H., Tio RA., Van Veldhuisen DJ; HEBE-III investigators Effects of erythropoietin aftera n acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III) Am Heart J 2008;155: Groenewegen HC, Onuta G, Goris M, Zandvoort A,, Van Gilst WH, Rozing J, De Smet BJ, Roks AJ, Hillebrands JL Non-bone marrow origin of neointimal smoot muscle cells in experimental in-stent restenosis J Vasc Res 2008;45:
7 How to remove thrombus prior to stenting in patients with acute myocardial infarction? Catheter Cardiovasc Interv 2008;72:204 A novel delta-protein-kinase inhibitor for adjunctive therapy during percutaneous coronary intervention Nat Clin Pract Cardiovasc Med 2008;5:446-7 Vermeulen RP, Jessurun GA, Peels HO, Jaarsma T, Clinical performance indicators for percutaneous coronary intervention. Crit Pathw Cardiol 2008;7: Dikkers R, Willems TP, Piers LH, De Jonge GJ, Tio RA, Van der Zaag-Loonen HJ, Van Ooijen PM,, Oudkerk M Coronary revascularization treatment based on dual-source computed tomography Eur Radiol 2008;18: Vlaar PJ, Diercks GF, Svilaas T, Vogelzang M, De Smet BJ, Van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, The feasibility and safety of routine thrombus aspiration in patients with non-stelevation myocardial infarction Catheter Cardiovasc Interv 2008;72: Vogelzang M, Loef BG, Regtien JG, Van der Horst IC, Van Assen H,, Nijsten MW Computer-assisted glucose control in critically ill patients Intensive Care Med 2008;34: Gu YL, Fokkema ML, The emerging role of thrombus aspiration in the management of acute myocardial infarction Circulation 2008;118: Fokkema ML, Vlaas PJ, Svilaas T Thrombus aspiration as definitive mechanical intervention for ST-elevation myocardial infarction: a report of five cases J Invasive Cardiol 2008;20:242-4 Piers LH, Salachova F, Slart RH, Vliegenthart R, Dikkers R, Hospers FA, Bouma HR, Zeebregts CJ, Willems TP, Oudkerk M,, Tio RA. The role of coronary artery calcification score in clinical practice BMC Cardiovasc Disord 2008;8:38 Tan ES, Jessurun G, Deurholt W, Van der Vleuten P, Van den Heuvel A, Ebels T,, Tio R Differences between early, intermediate, and late angioplasty after coronary artery bypass grafting Crit Pathw Cardiol 2008;7: Dieperink W, Nijsten MW, Van de Stadt M, Van der Horst IC, Aarts LP,, Jaarsma T Implementation of Boussignac continuous positive airway pressure in the coronary care unit: experiences and attitudes Heart Lung 2008;37: Piers LH, Dikkers R, Willem TP, De Smet BJ, Oudkerk M,. Tio RA
8 Computed tomographic angiography or conventional coronary angiography in therapeutic decision-making Eur Heart J 2008;29: Vlaar PJ, Svilaas T, Damman K, De Smet BJ, Tijssen JG, Hillege HL, Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systemic review Circulation 2008;118: De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Adjunctive manual thrombectomy improves myocardial perfusuion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Eur Heart J 2008;29: De Vos AM, Rutten A, Van de Zaag-Loonen HJ, Bots ML, Dikkers R, Buiskool RA, Mali WP, Lubbers DD, Mosterd A, Prokop M, Rensing Bj, Cramer MJ, Van Es HW, Moll FL, Van de Pavoordt ED, Doevendans PA, Velthuis BK, Mackaay AF,, Oudkerk M Non-invasive cardiac assessment in high risk patients (The GROUND study): rationale, objectives and design of a multi-center randomized controlled clinical trial Trials 2008;9:49 De Jonge GJ, Van Ooijen PM, Piers LH, Dikkers R, Tio RA, Willems TP, Van den Heuvel AF, Zijlstra F, Oudkerk M Visualization of anomalous coronary arteries on dual-source computed tomography Eur Radiol 2008;18: Groen JM, Greuter MJ, Vliegenthart R, Suess C, Schmidt B,, Oudkerk M Calcium scoring using 64-slice MDCT, dual source CT and EBT: a comparative phantom study Int J Cardiovasc Imaging 2008;24:547-56
9 Nationale tijdschriften Van der Meer P, Van Veldhuisen DJ Nieuwe toepassingen van erytropoëtine bij cardiovasculaire aandoeningen: van hematopoëse tot cardioprotectie Ned Tijdschr Geneeskd 2008;152:923-7 Vermeulen RP, Jaarsma T, Hanenburg FG, Nannenberg JW, Jesusrun GA, Prehospital diagnosis in STEMI patients treated by primary PCI: the key to rapid reperfusion Neth Heart J 2008;16:5-9 Van der Horst ICC, Van Veldhuisen DJ Bespreking Leerboek Hartfalen, 2 e, geheel herziene druk, onder redactie van Voors AA en Kirkels JH Ned Tijdschr Geneeskd 2008;19:1127 Jaarsma T, Van der Wal MH, Lesman-Leegte I, Luttik M.L. Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, Van Gilst WH, Lok DJA, Dunselman PHJM, Hillege HL, Van Veldhuisen DJ Waarde van lichte en intensieve begeleiding van patiënten met hartfalen; resultaten van het COACH-onderzoek Ned Tijdschr Geneeskd 2008;152: Huzen J, Van Veldhuisen DJ, Van Gilst WH, Van der Harst P Telomeren en biologische veroudering bij hart- en vaatziekten Ned Tijdschr Geneeskd 2009;152: Aalberts JJJ, Van den Berg MP, Bergman JEH, Du Marchie Sarvaas GJ, Post JG, Van Unen H, Pals G, Boonstra PW, Van Tintelen JP The many faces of aggressive aortic pathology: Loeys-Dietz syndrome Neth Heart J 2008;16: Wijpkema JS, Anthonio RL, Jessurun GA, Wijk WA, Tio RA, Restenosis begets restenosis: implications for stent selection Neth Heart J 2008;16: Langeveld BE, Henning RH, De Smet BJ,, Driessen, Tijsma E, Van Gilst WH, Roks A Rescue of arterial function by angiotensin-(1-7): towards improvement of endothelial function by drug-eluting stents Neth Heart J 2008;16:291-2 Gu YL, Svilaas T, Van der Horst IC, Conditions mimicking acute ST-segment elevation myocardial infarction in patients referred for primary percutaneous coronary intervention Neth Heart J 2008;16: Van der Laan A, Hirsch A, Nijveldt R, Van der Vleuten PA, Van der Giessen WJ, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WR, Zwaginga JJ, Biemond BJ, Van Rossum AC, Tijssen JG,, Piek JJ Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results Neth Heart J 2008;15:436-9
10
DATE: 29 August 2012 CONTEXT AND POLICY ISSUES
TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY
Annual Publication Report
Annual Publication Report 2008 TABLE OF CONTENTS 3 GRONINGEN INSTITUTE FOR KIDNEY DISEASES GIKD 8 CARDIOVASCULAR CENTER CVC 16 INSTITUTE FOR PHARMACOEPIDEMIOLOGY AND DRUG POLICY PEDP 20 GRONINGEN RESEARCH
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population. Carel Jan Willem Borleffs
Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population Carel Jan Willem Borleffs The studies described in this thesis were performed at the Department
Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013
Diagnostic and Therapeutic Procedures
Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,
Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
Canadian Journal of Cardiology 27 (2011) 529 533. Editorial
Canadian Journal of Cardiology 27 (2011) 529 533 Editorial From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting
Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
California Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
Utilizing the Cath Lab for Cardiac Arrest
Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013
REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO
REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
Prognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
Aktuelle Literatur aus der Notfallmedizin
05.02.2014 Aktuelle Literatur aus der Notfallmedizin prä- und innerklinisch Aktuelle Publikationen aus 2012 / 2013 PubMed hits zu emergency medicine 12,599 Abstract OBJECTIVES: Current American Heart
DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
For the NXT Investigators
Diagnostic performance of non-invasive fractional flow reserve derived from coronary CT angiography in suspected coronary artery disease: The NXT trial Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur,
Medical Tourism - The Role of Intervals inCardiovascular Cancer
Acute Decompensated Heart Failure: Time Critical Interventions MO-51 / 1 Hour Faculty: Matthew Strehlow, MD, FACEP Monday, 10/26/2015 / 3:30 PM - 4:20 PM The treatment of congestive heart failure (CHF)
Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
Management of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
Protocol. Cardiac Rehabilitation in the Outpatient Setting
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 07/01/14 Next Review Date: 09/15 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
Appendix. Costing Case Samples for OOHCA
Appendix Costing Case Samples for OOHCA The patient (ICD-1) Treatment Codes (OPCS 4) Patient 27 Admitted to ICU following percutaneous cardiac intervention (PCI) with 2 drugeluting stents following a VF
CARDIOLOGY Delineation of Privileges
CARDIOLOGY Delineation of Privileges APPLICANT: INITIAL APPOINTMENT REQUIREMENTS: BASIC EDUCATION: M.D. or D.O. from an accredited school of medicine or osteopathy. Successful completion of an ACGME or
MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging. Anne Günther Department of Radiology OUS Rikshospitalet
MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging Anne Günther Department of Radiology OUS Rikshospitalet CORONARY CT ANGIOGRAPHY (CTA) Accurate method in the assessment of possible
STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY
STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY Per Medical Board decision March 18, 2008: These credentialing standards do NOT apply to peripheral angiography performed in the context
Antonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
The Cardiac Society of Australia and New Zealand
The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures
Imaging of Thoracic Endovascular Stent-Grafts
Imaging of Thoracic Endovascular Stent-Grafts Tariq Hameed, M.D. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana Disclosures: No relevant financial
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne
How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne What do the guidelines say? What happens with warfarin
Regions Hospital Delineation of Privileges Cardiology
Regions Hospital Delineation of s Cardiology Applicant s Name: Last First M. Instructions: Place a check-mark where indicated for each core group you are requesting. Review education and basic formal training
Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH
Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH PAUL N. CASALE, M.D., F.A.C.C. Chief, Division of Cardiology and Medical Director of Cardiology, Lancaster General Hospital
Fort Hamilton Hospital Specialty: Cardiology Department of Medicine Delineation of Privileges
NAME Fort Hamilton Hospital Specialty: Cardiology Department of Medicine Delineation of Privileges GENERAL CARDIOLOGY Required Qualifications for General Cardiology Education/Training/Experience Must have
Rivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
CARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
Main Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
Your Guide to Express Critical Illness Insurance Definitions
Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses
MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION. POLICY NUMBER: 8.01.14 CATEGORY: Therapy/ Rehabilitation
MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
Treatment of cardiogenic shock
ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria
Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
Press. Siemens solutions support diagnosis and treatment of cardiovascular diseases
Press Healthcare Erlangen, August 29, 2015 ESC 2015: ExCel London Exhibition and Convention Center, Booth #G700 Siemens solutions support diagnosis and treatment of cardiovascular diseases New cardiovascular
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
LEADING-EDGE Cardiovascular Care
LEADING-Edge Cardiovascular Care Coral Gables Hospital North Shore Medical Center Hialeah Hospital Delray Medical Center Good Samaritan Medical Center Palm Beach Gardens Medical Center St. Mary s Medical
έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν
ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum
Michigan Heart & Vascular Institute ON THE ST. JOSEPH MERCY HOSPITAL CAMPUS, ANN ARBOR, MICHIGAN
ON THE ST. JOSEPH MERCY HOSPITAL CAMPUS, ANN ARBOR, MICHIGAN Dear Colleague: Cardiovascular medicine has marked an important milestone in the battle against heart disease. The latest available data indicates
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
Cardiac Rehabilitation CARDIAC REHABILITATION HS-091. Policy Number: HS-091. Original Effective Date: 3/16/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease Erich Minar Medical University Vienna for the Task Force on the Diagnosis and Treatment of Peripheral
Triple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon
Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?
Listen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
Electrocardiographic Body Surface Mapping
Electrocardiographic Body Surface Mapping Policy Number: 2.02.23 Last Review: 4/2016 Origination: 10/2009 Next Review: 10/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
GENERAL HEART DISEASE KNOW THE FACTS
GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to
Perioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on
Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
Employee Critical Illness Option
ECIO Employee Critical Illness Option Financial Protection for the Unexpected Includes Cancer Benefit First Occurrence Additional Occurrence Reoccurrence Spouse Coverage Available Child Coverage at No
FY2015 Final Hospital Inpatient Rule Summary
FY2015 Final Hospital Inpatient Rule Summary Interventional Cardiology (IC) Peripheral Interventions (PI) Rhythm Management (RM) On August 4, 2014, the Centers for Medicare & Medicaid Services (CMS) released
Interventional Cardiology Peripheral Interventions Rhythm Management
FY2016 Hospital Inpatient Rule (IPPS) Interventional Cardiology Peripheral Interventions Rhythm Management On April 17, 2015 the Centers for Medicare and Medicaid Services (CMS) released the Hospital Inpatient
NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3
1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications
ECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
The Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
ACLS Provider Manual Comparison Sheet Based on 2010 AHA Guidelines for CPR and ECC. BLS Changes
ACLS Provider Manual Comparison Sheet Based on 2010 AHA Guidelines for CPR and ECC CPR Chest compressions, Airway, Breathing (C-A-B) BLS Changes New Old Rationale New science indicates the following order:
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
Samir B. Pancholy, MD, FACC, FSCAI 570-840-9852
Samir B. Pancholy, MD, FACC, FSCAI 570-840-9852 Medical School: B.J. Medical College, Ahmedabad, India 6-1981 to 5-1987. Residency: State University of New York at Stony Brook, Stony Brook, NY, Internal
Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy
Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy File name: Cardiac Rehabilitation (Outpatient Phase II) File code: UM.REHAB.04 Origination: 08/1994 Last Review: 08/2011 Next Review:
